$HURA

TuHURA Biosciences, Inc./NV

TuHURA Biosciences is a clinical-stage immuno-oncology company developing therapeutics intended to address resistance to cancer immunotherapies. Its programs include the Immune Fx (IFx) platform, which uses innate immune agonists to make tumor cells appear bacterial to the immune system, and IFx2.0, its lead candidate being studied with pembrolizumab for advanced or metastatic Merkel cell carcinoma. TuHURA also holds rights to TBS-2025, a VISTA-inhibiting monoclonal antibody being developed for relapsed or refractory acute myeloid leukemia. Its Delta Opioid Receptor technology is used to develop bi-specific, bi-functional antibody-drug conjugates targeting immune-suppressing cells in the bone marrow and tumor environment. The company is headquartered in Tampa, Florida.

3
2
2

No SEC Form 4 filings for $HURA in the last 30 days.

See all $HURA insider activity →
Low

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences (NASDAQ: HURA) reported Q3 2026 results, highlighting progress in its immuno-oncology programs. The company shared early data from its IFx-2.0 study with Keytruda, showing durable responses in Merkel cell carcinoma patients. It also received FDA clearance for a Phase 1b study of its VISTA-inhibiting antibody, TBS-2025, in a subset of AML. TuHURA has $1.9M in cash and access to a $50M credit facility.

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

HURA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning HURA (TuHURA Biosciences, Inc./NV). Coverage has skewed bullish: 3 bullish, 2 neutral, and 2 bearish.

Recent HURA coverage spans corporate actions, financial news and earnings.

What's driving HURA

AlphAI scores every news story that mentions HURA with an AI model for sentiment and relevance, and aggregates insider trades from TuHURA Biosciences, Inc./NV's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HURA

Score
$HURALowDebt financing· $50M

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

$HURAMedEarnings

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences (NASDAQ: HURA) reported Q3 2026 results, highlighting progress in its immuno-oncology programs. The company shared early data from its IFx-2.0 study with Keytruda, showing durable responses in Merkel cell carcinoma patients. It also received FDA clearance for a Phase 1b study of its VISTA-inhibiting antibody, TBS-2025, in a subset of AML. TuHURA has $1.9M in cash and access to a $50M credit facility.

$HURALowDebt financing· $1.5M

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

$HURAHighAI 8/10

TuHURA reports tumor responses in 3-patient cancer trial

TuHURA Biosciences (HURA) reported partial tumor responses in 3 patients from a trial of IFx-2.0 combined with Keytruda for metastatic Merkel Cell Carcinoma. The Phase 1b/2a trial aims to enroll 9 patients and assesses safety and feasibility. The company is also conducting a Phase 3 trial. HURA hosted a webcast to discuss the initial data.

$HURALowDebt financing· $50M

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences (NASDAQ:HURA) received a U.S. patent for its Delta Opioid Receptor (DOR) technology, covering uses in cancer treatments, including ADCs and cellular immunotherapies. The patent, valid until 2043, aims to enhance cancer immunotherapy effectiveness by targeting MDSCs. TuHURA is advancing preclinical models for blood-related cancers like AML and MDS.

$HURALowDebt financing· $50M

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

$HURALowDebt financing· $650K

TuHURA Biosciences, Inc./NV (HURA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol

TuHURA Biosciences, Inc./NV (HURA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of the TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan On September 10, 2026, the Board of Director

Related tickers